These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 3413875)

  • 1. [Mistletoe therapy of metastasizing renal cancer. A phase II study].
    Kjaer M
    Ugeskr Laeger; 1988 Aug; 150(32):1923-8. PubMed ID: 3413875
    [No Abstract]   [Full Text] [Related]  

  • 2. High-dose medroxyprogesterone acetate in patients with renal adenocarcinoma and measurable lung metastases: a phase II study.
    Kjaer M; Frederiksen PL
    Cancer Treat Rep; 1986 Mar; 70(3):431-2. PubMed ID: 2937534
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II study of amsacrine in metastatic renal cell carcinoma: a Cancer and Leukemia Group B study.
    Amrein PC; Coleman M; Richards F; Poulin RF; Berkowitz I; Kennedy BJ; Green M; Herschkopf R; Rafla S
    Cancer Treat Rep; 1983 Nov; 67(11):1043-4. PubMed ID: 6688967
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II study of medroxyprogesterone acetate with tamoxifen in advanced renal cell cancer.
    Fuks JZ; Aisner J; Van Echo DA; Wiernik PH
    Cancer Treat Rep; 1982 Sep; 66(9):1773-4. PubMed ID: 7116354
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II study of nafoxidine in the therapy for advanced renal carcinoma.
    Feun LG; Drelichman A; Singhakowinta A; Vaitkevicius VK; Oishi N
    Cancer Treat Rep; 1979 Jan; 63(1):149-50. PubMed ID: 369688
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase II study of continuous 5-day vinblastine infusion in renal adenocarcinoma.
    Kuebler JP; Hogan TF; Trump DL; Bryan GT
    Cancer Treat Rep; 1984 Jun; 68(6):925-6. PubMed ID: 6733709
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase II trial of methyl-GAG in advanced renal cancer.
    Zeffren J; Yagoda A; Watson RC; Natale RB; Blumenreich MS; Chapman R; Howard J
    Cancer Treat Rep; 1981; 65(5-6):525-7. PubMed ID: 6263478
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II trial of spirogermanium in advanced renal cell carcinoma: a Cancer and Leukemia Group B study.
    Schulman P; Davis RB; Rafla S; Green M; Henderson E
    Cancer Treat Rep; 1984 Oct; 68(10):1305-6. PubMed ID: 6525606
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase II study of tamoxifen in patients with advanced renal cell carcinoma.
    Glick JH; Wein A; Torri S; Alavi J; Harris D; Brodovsky H
    Cancer Treat Rep; 1980; 64(2-3):343-4. PubMed ID: 7407768
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II trial of combination methyl-GAG and vinblastine in the treatment of metastatic renal adenocarcinoma.
    Todd RF; Garnick MB; Canellos GP
    Cancer Treat Rep; 1982 Jul; 66(7):1585-6. PubMed ID: 7093973
    [No Abstract]   [Full Text] [Related]  

  • 11. [Extracts of mistletoe in cancer therapy].
    Jensen K
    Ugeskr Laeger; 1982 Mar; 144(13):961-3. PubMed ID: 7101540
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase II evaluation of bisantrene in patients with advanced renal cell carcinoma.
    Evans WK; Shepherd FA; Blackstein ME; Osoba D; Taylor D
    Cancer Treat Rep; 1985 Jun; 69(6):727-8. PubMed ID: 4016779
    [No Abstract]   [Full Text] [Related]  

  • 13. Improvement of psoriasis and cutaneous side-effects during tyrosine kinase inhibitor therapy for renal metastatic adenocarcinoma. A role for epidermal growth factor receptor (EGFR) inhibitors in psoriasis?
    Wierzbicka E; Tourani JM; Guillet G
    Br J Dermatol; 2006 Jul; 155(1):213-4. PubMed ID: 16792781
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase II evaluation of chlorozotocin in patients with renal cell carcinoma.
    Gralla RJ; Yagoda A
    Cancer Treat Rep; 1979 Jun; 63(6):1007-8. PubMed ID: 157222
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II trial of dianhydrogalactitol in advanced renal cell carcinoma: a Southwest Oncology Group study.
    Ratanatharathorn V; Baker LH; Balducci L; Talley RW; Hoogstraten B
    Cancer Treat Rep; 1982 May; 66(5):1231-2. PubMed ID: 7083224
    [No Abstract]   [Full Text] [Related]  

  • 16. A phase II study of Catrix-S in solid tumors.
    Romano CF; Lipton A; Harvey HA; Simmonds MA; Romano PJ; Imboden SL
    J Biol Response Mod; 1985 Dec; 4(6):585-9. PubMed ID: 3878861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anguidine: a broad phase II study of the Southeastern Cancer Study Group.
    Adler SS; Lowenbraun S; Birch B; Jarrell R; Garrard J
    Cancer Treat Rep; 1984 Feb; 68(2):423-5. PubMed ID: 6697331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of diaziquone in advanced renal adenocarcinoma.
    Hansen M; Gallmeier WM; Vermorken J; Holdener E; Hansen HH; Renard J; Rozencweig M
    Cancer Treat Rep; 1984; 68(7-8):1055-6. PubMed ID: 6744342
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial.
    Friess H; Beger HG; Kunz J; Funk N; Schilling M; Büchler MW
    Anticancer Res; 1996; 16(2):915-20. PubMed ID: 8687151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of advanced adenocarcinoma of the kidney with mitolactol: a Southeastern Cancer Study Group Trial.
    Brubaker LH; Nelson MO; Birch R; Williams S
    Cancer Treat Rep; 1986 Feb; 70(2):305-6. PubMed ID: 3948194
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.